$NXTS News

Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage

Nexentis Technologies' MitoCareX Bio Subsidiary Completes Initial Computational Screening Stage Under Its Drug-Discovery Initiative With Boltz

Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis

Nexentis Deploys MitoCareX Computational Drug Discovery Infrastructure on Google Cloud

Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud

Nexentis Technologies Unit MitoCareX Bio Launches Its Computational Drug Discovery Infrastructure On Google Cloud Platform

Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

Nexentis Technologies Subsidiary MitoCareX Bio Narrows Its SLC Transport Protein Candidates To Select Candidate For A Drug Discovery Campaign

Nexentis Technologies Files Prospectus For Offering 2.573M Common Shares On Behalf Of Selling Shareholders

Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative

Nexentis Technologies Subsidiary Completes Analysis Of SLC Transport Proteins, Starts Global AI Drug Discovery Initiative With Boltz

Nexentis Shares Rise After Solar Project Monetisation Agreement (NXTS)

Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment

Nexentis Technologies Amends Its Loan And Partnership Agreement With Solterra Renewable Energy, Other Lenders For Melz Solar Project; Solterra To Make Early Partial Repayments Of ~$147K On Its Part Of Loan, $98K For Sale Of 10% Of Its Profit Rights;

Nexentis Technologies Files Prospectus For Offering 410,998 Common Shares At $7.056/Share

Nexentis Technologies Soars 156% Before Falling 46% After Hours — Here’s Why NXTS Stock Is Trending

Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery

Nexentis Technologies Subsidiary MitoCareX Bio Partners With AI Biomolecular Drug Discovery Research Lab Boltz To Accelerate Identification Of Novel Small-Molecule Scaffolds Targeting Selected Solute Carrier Proteins

Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases